| CTRI Number |
CTRI/2024/07/069957 [Registered on: 04/07/2024] Trial Registered Prospectively |
| Last Modified On: |
26/07/2024 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Nutraceutical |
| Study Design |
Other |
|
Public Title of Study
|
The effectiveness of NLSPL (Natural Life Speciality Pvt. Ltd) products on glycemic index and glycemic response in normal healthy adults: Prospective, Open label, Cross-over study |
|
Scientific Title of Study
|
The effectiveness ofNLSPL products on glycemic index and glycemic response in
normal healthy adults: Prospective, Open label, Cross-over study. |
| Trial Acronym |
NA |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| Protocol No.: NLSPL/GI/001 Version: 1.0 Date: 21/05/2024 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Almas Pathan |
| Designation |
Principal Investigator |
| Affiliation |
Jehangir Clinical Development Centre |
| Address |
Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001
Pune MAHARASHTRA 411001 India |
| Phone |
9763002830 |
| Fax |
|
| Email |
almas.jikare@rediffmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Neelambari Bhosale |
| Designation |
Head Clinical Operations |
| Affiliation |
CRO-Jehangir Clinical Development Centre |
| Address |
Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001
Pune MAHARASHTRA 411001 India |
| Phone |
9823783443 |
| Fax |
|
| Email |
neelambari@jcdc.co.in |
|
Details of Contact Person Public Query
|
| Name |
Dr Ruchi Joshi |
| Designation |
Head Strategic Partnerships |
| Affiliation |
CRO-Jehangir Clinical Development Centre |
| Address |
Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001
Pune MAHARASHTRA 411001 India |
| Phone |
9156384846 |
| Fax |
|
| Email |
ruchi.joshi@jcdc.co.in |
|
|
Source of Monetary or Material Support
|
| 1. Jehangir Clinical Development Centre,Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001 |
|
|
Primary Sponsor
|
| Name |
Natural Life Speciality Pvt. Ltd (NLSPL). |
| Address |
F-7, Sacred World Mall, Wanwadi, Pune 411040. Maharashtra |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Almas Pathan |
Jehangir Clinical Development Centre |
Jehangir Clinical Development Centre Pvt LTd, Deparment of Clinical Research, Ground floor,Jehangir Hospital Premises, 32 Sassoon Road Pune 411001 Pune MAHARASHTRA |
9763002830
almas.jikare@rediffmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Jehangir Clinical Development Centre |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
Healthy Adults |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Atta (P2) |
Investigational Product 2 Name: NLSPL Atta (P2)
Investigational Product Packaging: Pouch
Form: Powder
Dose: 66 gms
Administration: Each subject will be administered in form of Rotis and consumed by the subject in 10 minutes
Duration: The treatment duration will be up to 1 day for each product in a cross over manner. |
| Intervention |
Honey (P4) |
Investigational Product 4 Name: NLSPL Honey (P4)
Investigational Product Packaging: Pouch
Form: Liquid
Dose: 62.2 gms
Administraion: Each subject will be administered in form of Honey solution and consumed by the subject in 10 minutes
Duration: The treatment duration will be up to 1 day for each product in a cross over manner. |
| Intervention |
Jaggery (P3) |
Investigational Product 3 Name: NLSPL Jaggery (P3)
Investigational Product Packaging: Pouch
Form: Granules/Powder
Dose: 53.2 gms
Administraion: Each subject will be administered in form of Jaggery solution and consumed by the subject in 10 minutes
Duration: The treatment duration will be up to 1 day for each product in a cross over manner. |
| Comparator Agent |
Reference ProductName: Standard Glucose (R1) |
Investigational Product Packaging: Pouch
Form: Granules
Dose: 50g
Administraion:Each subject will be administered as sugar solution and consume in 10 minutes |
| Intervention |
Sugar (P1) |
Investigational Product 1 Name: NLSPL Sugar (P1)
Investigational Product Packaging: Pouch
Form: Granules
Dose: 50 gms
Administration:Each subject will be administered as sugar solution and consume in 10 minutes.
Duration: The treatment duration will be up to 1 day for each product in a cross over manner. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
45.00 Year(s) |
| Gender |
Both |
| Details |
To be eligible for this trial, subjects must fulfill all inclusion criteria listed below:
1. Healthy Males and/or Female subjects with the age group 18 to 45 years.
2. The subject should be not obese with a Body mass index (BMI) in the range ≥18.5 to ≤ 24.9 3.
3.The subject should be willing to refrain from smoking, alcohol, and caffeine containing drinks during the study period.
4. The subject should be willing to comply with study protocol requirements including adherence to diet and lifestyle modifications.
5. Subject with random blood sugar ≤ 200 mg/dl
6. The subject should be willing to provide a voluntary written informed consent.
|
|
| ExclusionCriteria |
| Details |
Subject meeting any of the following exclusion criteria will not be eligible for participation in this trial:
1. Diabetic Individual, type I/II diabetics, Gestational Diabetes
2. Subject who has been diagnosed to have acute infections like viral fever, typhoid, cold, diarrhea within one month prior to enrollment.
3. Subject with a history of complications such as respiratory disorders, cancer or heart attack and stroke
4. History of malignancy in the past 1 year.
5. Having an eating disorder
6. History of hypoglycemia in last 3 months
7. Taking any herbal/Ayurveda/Traditional preparation that could profoundly affect blood glucose
8. Pregnant and lactating women
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
To evaluate the glycemic index and glycemic response of NLSPL product Sugar (P1) in comparison to standard glucose (R1).
To evaluate the glycemic index and glycemic response of NLSPL product Atta (P2) in comparison to standard glucose (R1).
To evaluate the glycemic index and glycemic response of NLSPL product Jaggery (P3), in comparison to standard glucose (R1).
To evaluate the glycemic index and glycemic response of NLSPL product Honey (P4) in comparison to standard glucose (R1).
|
This is a cross over study with 7 scheduled visits with treatment duration of 1 day for each product.
timepoint:
Visit 2 and Visit 5: Standard Glucose (R1)
Visit 3,Visit 4, Visit 6 and Visit 7: NLSPL product Sugar (P1), NLSPL product Atta (P2), NLSPL product Jaggery (P3),NLSPL product Honey (P4)
|
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To assess the safety of NLSPL Sugar (P1), Atta (P2), Jaggery (P3), Honey (P4) products in subjects. |
This is a cross over study with 7 scheduled visits with treatment duration of 1 day for each product.
timepoint:
Visit 2 & Visit 5: Standard Glucose (R1)
Visit 3,Visit 4, Visit 6 & Visit 7: NLSPL product Sugar (P1), NLSPL product Atta (P2), NLSPL product Jaggery (P3),NLSPL product Honey (P4)
|
|
|
Target Sample Size
|
Total Sample Size="12" Sample Size from India="12"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
04/07/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0" Months="0" Days="16" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
This is an open-label crossover study aiming to
investigate the glycemic index, glycemic response, and safety of NLSPL products
Sugar (P1), Atta (P2), Jaggery (P3), Honey (P4) in comparison to standard
glucose (R1) as reference product. The study is planned to enroll a total of 12
normal healthy adults aged 18 to 45 years. Participants will receive
comprehensive information regarding the nature and objectives of the study. The
study procedures will begin only after obtaining written informed consent from the
participant. The study investigator/study team will identify prospective
participants based on the screening procedure and their qualifications against
the study’s inclusion/exclusion criteria. Subjects satisfying the study
eligibility criteria will be enrolled.
On screening day subject’s medical history,
Demographic data (Age, Gender, Height, Weight, BMI), Random blood sugar (Finger
Prick method), UPT kit (Only for females in child bearing age), vital signs
(Heart rate, seated blood pressure, respiratory rate, body temperature), prior
and concomitant medication and Physical examination will be done. While doing
random blood sugar using finger-prick method participants in the study protocol
will be encouraged to warm their hands before the finger-prick procedure to
facilitate blood flow. Consistently, the third finger on the participant’s left
hand will be utilized for finger-prick sampling during blood collection. Care
will be taken to avoid fingertip blood extraction by refraining from squeezing,
thereby preventing potential dilution of blood with plasma. Female volunteers
will not be tested during menstrual period dates; testing will be rescheduled
in such cases and in case of visits rescheduled beyond window period, a
protocol deviation should be reported with appropriate reason.
After the screening visit, all subjects will undergo a
comprehensive six-day testing regimen, comprising two days with the standard
glucose (R1) and four days with the NLSPL product (IP)-Sugar (P1), Atta (P2),
Jaggery (P3), and Honey (P4).
Subjects will be asked to visit the site at Visit 2, Visit 3,
Visit 4, Visit 5, Visit 6, and Visit 7 after 12 hours of overnight fasting.
Subjects will be gently reminded to avoid consuming any food or nutritional
products, apart from water, before undergoing study procedures. During each
visit, vital signs (Heart rate, seated blood pressure, respiratory rate, body
temperature) and Prior and Concomitant medication (if any) will be done. Each
Subject will then be instructed to consume the standard glucose (R1) during
designated visits (visit 2 and visit 5) and NLSPL Products (IP) - Sugar (P1),
Atta (P2), Jaggery (P3), and Honey (P4) during visit 3, visit 4, visit 6 and
visit 7.
To evaluate the performance of the IP, venous
blood sugar measurements will be taken as Fasting Blood Sugar (FBS) at 0
minutes before product administration, followed by assessments at 15, 30, 60,
90, 120-, and 150-minutes post-administration during visits 2, Visit 3, visit
4, visit 5, visit 6 and visit 7/End of study, as outlined in the schedule of
events. A minimum washout period of two days will be implemented between
measurements to mitigate potential carry-over effects effectively. At the end
of 16 days for all 12 subjects, data will be statistically analyzed and changes
in FBG and blood sugar level will be estimated as a trend in comparison for the
estimation of glycemic index of NLSPL products Sugar (P1), Atta (P2), Jaggery
(P3), and Honey (P4).
Study details include:
· The
study duration will be up to 16 days.
· The
treatment duration will be up to 1 day for each product in a cross over manner.
· The
visits frequency will include 7 scheduled physical visits |